Unknown

Dataset Information

0

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.


ABSTRACT: Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival. This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase   (IDO/TDO) inhibitors.

SUBMITTER: Li H 

PROVIDER: S-EPMC6761178 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7419300 | BioStudies
2010-01-01 | S-EPMC4533844 | BioStudies
1000-01-01 | S-EPMC4191572 | BioStudies
1000-01-01 | S-EPMC5259766 | BioStudies
2020-01-01 | S-EPMC7494748 | BioStudies
2001-01-01 | S-EPMC1221754 | BioStudies
2007-01-01 | S-EPMC3326534 | BioStudies
2020-01-01 | S-EPMC7072257 | BioStudies
2010-01-01 | S-EPMC2939288 | BioStudies
2019-01-01 | S-EPMC6828782 | BioStudies